A double-blind study comparing benoxaprofen, aspirin, and benoxaprofen plus aspirin in patients with rheumatoid arthritis.
Ten patients with rheumatoid arthritis completed a study that consisted of 30-day treatment periods with aspirin, benoxaprofen, and benoxaprofen plus aspirin. There were two-week placebo washouts between each treatment. The patients were evaluated biweekly for 15 variables. Each variable was compared for each period; a pooled index was calculated on three combinations of variables. The benoxaprofen-plus-aspirin combination was significantly better than aspirin and better than benoxaprofen alone. This study indicates that combining nonsteroidal anti-inflammatory drugs which inhibit different sites of the inflammatory response (i.e., benoxaprofen, an inhibitor of the directional migration of monocytes, with aspirin, a potent inhibitor of prostaglandin synthesis) may be advantageous in treating patients with rheumatoid arthritis.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D011422:Propionates; C011677:benoxaprofen; D001241:Aspirin